drugset / Trial / NCT01415518
Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
Efficacy and tolerability study in severe chronic obstructive pulmonary disease (COPD) patients.
Timeline
- Start
- 2011-09-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
Outcome
Met primary endpoint
registry Symbicort Turbuhaler + Ipratropium + Theophylline SR vs Ipratropium + Theophylline SR; p <.0001; Ratio 1.069 (95% CI 1.043 to 1.096); ANCOVA NCT01415518 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | budesonide/formoterol | Unknown | 4.5 ug | Inhaled |
| Subject | budesonide/formoterol | Unknown | 160 ug | Inhaled |
| Background | Ipratropium | Small molecule | 20 ug | Inhaled |
| Background | Theophylline | Small molecule | 0.1 g | Oral |